http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2233330-C2
Outgoing Links
Predicate | Object |
---|---|
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate | 1995-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2004-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02218e1007b9b7fcf1eba8f23ea6b36c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_658d420ffdc4063594ce5fe926d5541a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_912892aa20162b4b7bec5a66f7e6cab8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53a2254c9a874ddf009e18c334529e86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7dea80dad3578ba2948388f09719200 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e98e62aa9690079a86425cde92beebb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c90b5da5f8ea7617eb67636edeb2bf60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b4f02248aec1d6395dc35687c9584d7 |
publicationDate | 2004-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2233330-C2 |
titleOfInvention | Nucleic acid molecule encoding ligand tie-2, ligand tie-2 and method for its preparing, vector, strain of cells cos, antibody, conjugate of ligand tie-2, ligand body, pharmaceutical composition, method for prophylaxis or attenuation of neovascularization and method for identification of tie-2 receptor antagonist |
abstract | FIELD: genetic engineering, molecular biology, biochemistry, medicine, pharmacy. n SUBSTANCE: invention relates to genes encoding tyrosine kinases and can be used for diagnosis. Human ligand TIE-2 represents TIE-2 receptor antagonist. Ligand TIE-2 is prepared using vector pBluescript KS that comprises nucleic acid encoding ligand TIE-2. Conjugate is prepared by coupling ligand TIE-2 with cytotoxic agent. Ligand body represents ligand TIE-2 fused with immunoglobulin contact site. Pharmaceutical composition contains effective amount of ligand TIE-2 or ligand body and it is used in method for prophylaxis or attenuation of neovascularization. Invention provides diagnosis and treatment of diseases associated with endothelial cells comprising TIE-2 receptors. Invention provides the development of diagnostic systems for identification of TIE-2 receptor antagonist. n EFFECT: improved prophylaxis and treatment method, valuable medicinal properties of ligand. n 16 cl, 14 dwg, 12 ex |
priorityDate | 1994-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1081.